Advanced glycosylated end products restrain the osteogenic differentiation of the periodontal ligament stem cell

Zhu-Ling Guo a,b, Shan-Ling Gan a, Chun-Yi Cao a, Rao Fu a, Sheng-Ping Cao a, Chen Xie a, Jing-Wei Chen a, Alex Gibson a, Xu Zheng a,b,*1, Nai-chia Teng c,d,**1

a School of Dentistry, Hainan Medical University, Hainan, PR China
b Department of Dentistry, The First Affiliated Hospital of Hainan Medical University, Hainan, PR China
c School of Dentistry, College of Oral Medicine, Taipei Medical University, Taiwan
d Department of Dentistry, Taipei Medical University Hospital, Taiwan

Received 20 February 2019; Final revision received 6 March 2019
Available online 16 April 2019

Keywords
AGEs (advanced glycosylated end products); PDLSCs (periodontal ligament stem cells); Periodontal disease; Diabetes mellitus; Prevention

Abstract  Background/purpose: Many studies have confirmed that periodontal disease interacts with diabetes. The aim of this study was to examine whether the advanced glycosylated end products (AGEs), which are generated by diabetics, have important effects on the osteogenic differentiation of periodontal ligament stem cells (PDLSCs).

Materials and methods: In this study PDLSCs were isolated from the periodontal ligaments of extracted third molar teeth. The subjects were divided into two groups, which included the normal control group (N-PDLSCs) and the AGEs-stimulating group (A-PDLSCs). Changes of receptor of AGEs (RAGE) and cumulative ROS in PDLSCs were monitored by western blot and flow cytometry, respectively.

Results: In the study AGEs noticeably inhibited the osteogenic differentiation of PDLSCs, with significant lower calcification nodules detected in A-PDLSCs (P < 0.01). RAGE expression level and ROS accumulation in A-PDLSCs were clearly higher than those in N-PDLSCs (P < 0.01).

Conclusion: Our conclusions were that AGEs may cause the apoptosis of stem cells, which could lead to the disorder of bone differentiation function of PDLSCs.

© 2019 Association for Dental Sciences of the Republic of China. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Periodontitis is a progressive disease characterized by the loss of periodontal tissues, particularly the alveolar bone. The prevalence of adult periodontal disease in China is as high as 80–90%, and is the main cause of adult tooth loss in this country. Previous studies have shown that stem cells exist in the pulp, exfoliated teeth and normal periodontal tissues of adult teeth, of which periodontal ligament stem cells (PDLSCs) are subtypes that can differentiate into osteoblasts, osteocytes, fibroblasts and so on. These then produce dental bone-like structures that move along the connective tissue of the periodontal membrane. They also affect typical periodontal ligament-like tissues to regenerate tissues damaged by periodontitis. Its regeneration potential contributes to its self-renewal and multi-differentiation ability, especially osteogenesis differentiation. It is suggested that PDLSCs can provide an important cell source for the treatment of periodontal disease mediated by stem cells.

Studies have revealed that, there is a complex internal relationship between periodontitis and diabetes mellitus. The two diseases are risk factors for each other and promote the progress of the diseases in conjunction with each other. People with chronic adult periodontitis and type 2 diabetes mellitus have a strong immunoreactivity induced by lipopolysaccharide, which is related to the severity of the pre-existing periodontal disease, revealing the cause of periodontitis susceptibility in a diabetic population. High glucose levels can promote lipopolysaccharide to induce gingival epithelial cells to secrete inflammatory factors, and also can increase the expression of toll-like receptor 4 (TLR4) in gingival epithelial cells resulting in periodontal tissue loss. Detrimental periodontal tissues can cause interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) to be released in large amounts, which in turn leads to insulin resistance. The TNF-α level of periodontitis patients plays an important influence on diabetes mellitus as a disease. Meanwhile, TNF-α can also promote bone absorption and inflammation. IL-6 can enhance the expression of vascular endothelial growth factor in periodontal tissues, leading to the increase of inflammatory cells in periodontal tissues, aggravating the inflammatory response and inhibiting the growth of periodontal ligament cells. Periodontal therapy can decrease the inflammation level of the periodontal tissues, and help to reduce the blood glucose level and insulin resistance in patients with type 2 diabetic periodontitis. Therefore, the treatment of periodontitis has important significance for diabetes prevention and treatment.

The prevalence of periodontitis in patients with type 2 diabetes mellitus for more than 5 years exceeds 85%. Studies have shown that advanced glycosylated end products (AGEs) deposit locally in gingival tissues in diabetic patients with long-term hyperglycemia. AGEs are the end-stage products of non-enzymatic saccharification, which play an important role in the pathogenesis of diabetes mellitus. The receptor of AGEs (RAGE) take essential part in accelerating the process of diabetic periodontitis and alveolar bone loss. According to research on the AGES-RAGE system may be a dominant pathway leading to the vicious cycle of tissue damage and repair in diabetic periodontitis. Periodontitis can decrease the expression of KAT2A gene in PDLSCs, activating the classical Wnt pathway. And the microenvironment of chronic periodontal inflammation can reduce the differentiation potential of PDLSCs. Both can inhibit the osteogenic differentiation of PDLSCs and promote the processes of periodontitis.

Materials and methods

Materials

Periodontal tissues were obtained from the extracted third molar teeth at the department of Oral and Maxillofacial surgery in the First Affiliated Hospital of Hainan Medical University. Totally 24 teeth used in the experiment were extracted from young men between the ages of 20 and 30. The teeth were free from infection, and patients were free from systemic diseases. The study was carried out under ethical guidelines and with the consent of each patient involved in the study. The tissue cleanser was PBS containing 10% FBS. The primary cell culture medium was DMEM containing 10% FBS. Basal medium of STEMPRO osteocyte contained 10% osteogenesis supplement. The cell digestion solution was 0.25% EDTA trypsin. All of the above cell culture reagents were purchased from GIBCO. Fluorescence direct labeling antibodies including STRO-1, CD146, CD34 and CD45 were purchased from the Abcam company. Primary antibody of RAGE and HRP labeled second antibody were purchased from SANTA CRUZ and CST, respectively. AGE-BSA was purchased from CALBIOMAC, and carboxy-H2DCFDA ROS Kit was purchased from Invitrogen.

The harvesting of PDLSCs

Soon after extracting the third molar teeth, the epithelial tissues and other connective tissues were surgically removed. The periodontal tissues from the middle one third part of the tooth root were harvested and prepared into around 1 mm² tissue blocks. Then the tissue blocks were placed in a culture dish with 10% FBS and incubated at 37°C with 5% CO₂ in an incubator for 2 h. Once the tissue blocks attached to the bottom of the culture plate, the primary cell culture medium were added. We changed the medium every two days and cultured the cells for 1–2 weeks. After cell migration from tissue blocks, single cell cloning was labeled and cultured for 1 week, the cells were kept for routine subculture.

The identification of PDLSCs

PDLSCs were cultured to the 2nd to 3rd generation. Then we digested the cells, resuspended them with PBS containing 5% FBS and adjusted the density to 1 × 10⁶/mL. Fluorescence directly labeled stem cell surface marker antibodies were used to confirm the PDLSCs, of which
STRO-1 and CD146 were positive and CD34 and CD45 were negative by flow cytometry.

The detection of osteogenic differentiation

PDLCs were cultured to the 3rd to 5th generation and divided into 4 groups, STEMPro osteocyte basal medium contained 10% osteogenesis supplement was used. In the process of cell differentiation, AGE-BSA (0, 50, 100 and 200ug/mL) was added to stimulate the PDLCs for 2 weeks. Then 2% alizarin red reagent was applied for staining to detect the osteogenic differentiation of PDLCs.

Western blot examination

AGE-BSA (0, 50, 100 and 200ug/mL) was used to stimulate the PDLCs for 2 weeks. Cell Proteins were collected using cell protein lysate. To detect the RAGE expression level, the proteins were separated via SDS-PAGE and transferred to PVDF membrane. The dilution ratio for primary antibody of RAGE and HRP labeled second antibody was 1:500 and 1:10000, respectively. The density of the protein bands was calculated by Quantity-one software.

The detection of ROS generation

AGE-BSA (200ug/mL) was added to stimulate PDLCs for 24 h. Cells were flushed with warm HBSS twice. H2DCFDA probes were non-fluorescent in their initial form and the conversion of H2DCFDA involved oxidation. After the H2DCFDA (25uM) was added, PDLCs were incubated for 60 min at 37 °C, avoiding light. Then Hoechst33342 (1.0 uM) was added for further flow cytometry test. Fluorescence of the H2DCFDA-treated PDLCs could depend and reflect on the intracellular ROS level.

Data analysis

All the above examinations were repeated three times. SPSS 23.0 statistical software was applied to analyze the results. All data was expressed by means ± SEM, and the unpaired, two-tailed Student t test was used for comparison between groups. \( P < 0.05 \) was considered as statistically significant.

Results

Culture and identification of PDLCs

PDLCs were cloned after culturing for 7 days, and grew like fibrous cells (Fig. 1A). PDLCs were positive for STRO-1 and CD146, while negative for CD34 and CD45 (Fig. 1B). The identification of primary PDLCs was confirmed by flow cytometry three times. The average percentage of positive marker cells of CD 146, STRO-1, CD45 and CD34 was 91%, 84%, 13% and 6%, respectively. Different passage of PDLCs developed for further experiments should be re-identified before use.

AGE-BSA could inhibit the osteogenic differentiation of PDLCs

We used different doses of AGE-BSA (50, 100 and 200ug/mL) to stimulate PDLCs and made a test of osteogenic differentiation. AGE-BSA noticeably inhibited osteogenic differentiation of PDLCs (Fig. 2A). The percentage of osteogenic calcification nodules of PDLCs in the experimental group was obviously lower than that in the control group (Fig. 2B). AGE-BSA showed dose-dependent inhibition to the osteogenic differentiation of PDLCs. 100 and 200ug/mL AGE-BSA
had the most significant effects on inhibiting the osteogenic differentiation of PDLSCs ($P < 0.01$).

**AGE-BSA could increase the expression of RAGE in PDLSCs**

With AGE-BSA (50, 100 and 200ug/mL) stimulation, the RAGE expression level of PDLSCs was detected by western blot (Fig. 3A). Compared with the normal control group (N-PDLSCs), the expression of RAGE in AGES-stimulating group (A-PDLSCs) was obviously enhanced (Fig. 3B). 100 and 200ug/mL AGE-BSA had the most significant effects on promoting the expression of RAGE in PDLSCs ($P < 0.01$).

**AGE-BSA could induce ROS accumulation in PDLSCs**

Intracellular ROS accumulation in A-PDLSCs was clearly enhanced than in N-PDLSCs (Fig. 4A). With AGE-BSA (200ug/mL) stimulating for 24 h, the fluorescence intensity of ROS in PDLSCs significantly increased ($P < 0.01$) (Fig. 4B).

**Discussion**

Previous studies on the relationship between chronic adult periodontitis and diabetes mellitus have found that locally deposited AGES can reduce the production of the extracellular matrix, decrease the expression of collagen, hinder the differentiation and maturation of osteoblasts, mediate the apoptosis and delay the repair of the periodontal tissues. Our investigation found that AGES significantly inhibit bone differentiation of the PDLSCs in a dose-dependent manner. The results supported that compared with non-diabetic patients, periodontal tissue loss and necrosis is more severe in patients with diabetes mellitus. This is because of a direct correlation between the effects of AGES and the detrimental effects on PDLSCs.

**Figure 2** The inhibitory effect of AGE-BSA on the osteogenic differentiation of PDLSCs. (A) With AGE-BSA (50, 100 and 200ug/mL) stimulation for two weeks, the osteogenic differentiation and calcification nodules of PDLSCs was calculated by alizarin red staining. Pictures were taken under a 100X light microscope. (B) Compared with the normal control group (N-PDLSCs), the osteogenic calcification nodules in AGES-stimulating group (A-PDLSCs) was obviously reduced. The error bars showed means $\pm$ SEM in triplicate experiments. $**P < 0.01$ by an unpaired two-tailed t test.

**Figure 3** The effect of AGE-BSA on RAGE expression in PDLSCs. (A) Evaluation on RAGE expression level with two-week AGE-BSA stimulation via western blot. As an appropriate protein-loading control, $\beta$-actin was used for both N-PDLSCs and A-PDLSCs. (B) AGE-BSA (100 and 200ug/mL) could significantly enhance the expression of RAGE in PDLSCs ($P < 0.01$). The error bars showed means $\pm$ SEM in triplicate experiments. $**P < 0.01$ by an unpaired two-tailed t test.
In this study, it was also found that AGEs could induce a dose-dependent increase in RAGE expression and an abnormal ROS accumulation level in PDLSCs. RAGE are expressed on a variety of cell surfaces, and previous studies have shown that canonical intracellular signals, including MAPK and WNT signaling pathways were cascaded with the combination of AGEs and RAGE. 17,22,23 It has been found that the MAPK signaling pathway is the key for bone development and homeostasis, and it also plays an important role in bone differentiation of PDLSC. 32,33 The activation of the MAPK signaling pathway is directly related to the secretion of proinflammatory cytokines. 19,21,23,24 Many studies suggest that the high expression of β-catenin in PDLSCs reduces osteogenesis and cellular differentiation via WNT signaling pathway. 34 With β-catenin accumulation in the cytoplasm, the stable β-catenin is transferred to the nucleus and mediates the transcription of downstream genes. Furthermore, the accumulation of intracellular ROS is a critical pathological mechanism of diabetes mellitus. 20,22–24 The findings of our study warrant further investigation of this important part of the relationship between diabetes mellitus as a systemic disease and its effect on chronic adult periodontitis and vice versa.

Periodontitis and several systemic diseases are already recognized as being closely related. 38,39 Researchs on the related mechanism have focused on the periodontal tissues response to specific periodontal pathogens, high inflammatory phenotype of monocytes, impaired adhesion, chemotaxis and phagocytosis of neutrophils. Studies similar to ours are uncommon and seldom focused on the osteoblast differentiation of PDLSCs by AGEs. As an autologous source of adult stem cells, PDLSCs have potential therapeutic application value to patients with diabetes mellitus. 2–4 Studies similar to ours are uncommon and relate to other factors. The findings of this study provided some preliminary experimental evidence for the application of PDLSCs in clinical treatment, which also play an important role in the prevention and treatment of periodontal disease in diabetic patients. Moreover, active controlling the incidence of periodontal disease and widely encouraging people to establish the preventive awareness should be promoted to the general population with or without systemic diseases.

Our current results proved that AGEs promote the accumulation of intracellular ROS by increasing the expression of RAGE, which ultimately leads to the increased inflammatory response and disorder in the osteogenic differentiation of PDLSCs. In conclusion, diabetes mellitus and chronic adult periodontitis are being closely related. AGEs may cause the apoptosis of stem cells, which could noticeably inhibit the osteogenic differentiation of PDLSCs.

Conflicts of interest

The authors declare no conflict of interest.

Acknowledgments

This research was funded by Hainan Provincial Natural Science Foundation of China, China (817330), Young Talents’ Science and Technology Innovation Project of Hainan Association for Science and Technology, China (QCXM201817), Education Department of Hainan Province, China (Hnky2017-31), Youth Development Fund Project of the First Affiliated Hospital of Hainan Medical University, China (HYFYYP201702), Course Construction Project of Hainan Medical University, China (HYJW201834), Medical Education Research Project of Medical Education Branch of Chinese Medical Association, China (2018B-N12003).

References

1. Seo BM, Miura M, Gronthos S, et al. Investigation of multipotent postnatal stem cells from human periodontal ligament. Lancet 2004;364:149–55.
2. Abbass MM, Korany NS, Salama AH, Dmytryk JJ, Safiejko-Mroczka B. The relationship between receptor for advanced glycation end products expression and the severity of periodontal disease in the gingiva of diabetic and non-diabetic periodontitis patients. Arch Oral Biol 2012;57:1342–54.
3. Park JY, Jeon SH, Choung PH. Efficacy of periodontal stem cell transplantation in the treatment of advanced periodontitis. Cell Transplant 2011;20:271–85.
4. Song IS, Han YS, Lee JH, Um S, Kim HY, Seo BM. Periodontal ligament stem cells for periodontal regeneration. Curr Oral Health Rep 2015;2:236–44.

5. Zhu WJ, Liang M. Periodontal ligament stem cells: current status, concerns, and future prospects. Stem Cell Int 2015;2015:972313.

6. Liu Q, Hu CH, Zhou CH, et al. DKK1 rescues osteogenic differentiation of mesenchymal stem cells isolated from periodontal ligaments of patients with diabetes mellitus induced periodontitis. Sci Rep 2015;5:13142.

7. Sun WL, Chen LL, Zhang SZ, Wu YM, Ren YZ, Qin GM. Inflammatory cytokines, adiponectin, insulin resistance and metabolic control after periodontal intervention in patients with type 2 diabetes and chronic periodontitis. Intern Med 2011;50:1569–71.

8. Lakschevitz F, Aboodi G, Tenenbaum H, Glogauer M. Diabetes and periodontal disease: interplay and links. J Curr Diabetes Rev 2011;7:433–9.

9. Miranda TS, Feres M, Retamal-Valdés B, Perez-Chaparro PJ, Maciel SS, Duarte PM. Influence of glycemic control on the levels of subgingival periodontal pathogens in patients with generalized chronic periodontitis and type 2 diabetes. Appl Oral Sci 2017;25:82–9.

10. Gurav AN. Management of diabolical diabetes mellitus and periodontal diseases: interplay and links. J Curr Diabetes Rev 2011;7:433–9.

11. Guo Y, Guo LN, Zhu JF, Tang CY, Feng YZ, Zhou HD. Associations of salivary BPIFA1 protein in chronic periodontitis patients with type 2 diabetes mellitus. Int J Endocrinol 2017;2017:1087017.

12. Masi S, Orlandi M, Parkar M, et al. Mitochondrial oxidative stress, endothelial function and metabolic control in patients with type II diabetes and periodontitis: a randomised controlled clinical trial. Int J Cardiol 2019;271:263–8.

13. Guo LN, Yang YZ, Feng YZ. Serum and salivary Territin and Hecpinid levels in patients with chronic periodontitis and type 2 diabetes mellitus. BMC Oral Health 2018;18:63–71.

14. Kim AR, Kim JH, Kim A, et al. Simvastatin attenuates tibial bone loss in rats with type 1 diabetes and periodontitis. J Trans Med 2018;16:306–14.

15. Mesia H, Gholami F, Huang H, et al. Systemic inflammatory responses in patients with type 2 diabetes with chronic periodontitis. BMJ Open Diabetes Res Care 2016;4:e000260.

16. Okuda M, Taguchi Y, Takahashi S, Tanaka A, Umeda M. Effects of high glucose for hard tissue formation on type II diabetes model rat bone marrow cells in vitro. Hard Tissue Biol 2015;24:77–83.

17. Yang X, Zhang J, Ni J, et al. Toli-like receptor 4 mediated hyper-responsiveness of gingival epithelial cells to LPS in high-glucose environment. J Periodontol 2014;85:1620–8.

18. Armitage GC, Wu Y, Wang HY, Sorrell J, Giovine F, Duff G. Low prevalence of a periodontitis-associated interleukin-1 composite genotype in individuals of Chinese heritage. J Periodontol 2000;2:164–71.

19. Guo ZL, Richardson DR, Kalinowski DS, Kovacevic Z, Tan-Un KC, Chan GCF. The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms. J Hematol Oncol 2016;9:98–113.

20. Min S, Wang C, Lu WL, et al. Serum levels of the bone turnover markers dickkopf-1, osteoprotegerin, and TNF-α in knee osteoarthritis patients. Clin Rheumatol 2017;36:2351–8.

21. Guo ZL, Yu B, Ning BT, et al. Genetically modified "obligate" anaerobic Salmonella typhimurium as a therapeutic strategy for neuroblastoma. J Hematol Oncol 2015;8:99–110.

22. Taylor JJ, Preshaw PM, Lalla E. A review of the evidence for pathogenic mechanisms that may link periodontitis and diabetes. J Clin Periodontol 2013;84:5113–34.

23. Lalla E, Papapanou PN. Diabetes mellitus and periodontitis: a tale of two common interrelated diseases. Nat Rev Endocrinol 2011;7:738–48.

24. Wang TF, Jen IA, Chou C, Lei YP. Effects of periodontal therapy on metabolic control in patients with type 2 diabetes mellitus and periodontal disease: a Meta-Analysis. Medicine 2014;93:e292.

25. King GL. The role of inflammatory cytokines in diabetes and its complications. J Periodontol 2008;79:1527–34.

26. Rui L, Aguirre V, Kim JK, et al. Insulin/IGF-1 and TNF-α stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J Clin Invest 2001;121:181–9.

27. Deng C, Sun Y, Liu H, Wang W, Wang JM, Zhang FM. Selective adipogenic differentiation of human periodontal ligament stem cells stimulated with high doses of glucose. PLoS One 2018;13:e0199603.

28. Assem M, Kamal S, Sabry D, Soliman N, Aly RM. Preclinical assessment of the proliferation capacity of gingival and periodontal ligament stem cells from diabetic patients. Open Access Maced J Med Sci 2018;6:254–9.

29. Jaramillo R, Shuck SC, Chan YS, et al. DNA advanced glycation end products (DNA-AGEs) are elevated in urine and tissue in an animal model of type 2 diabetes. Chem Res Toxicol 2017;30:689–98.

30. Acharya A, Shetty S, Deshmukh V. Periodontal ligament stem cells: an Overview. J Oral Biosci 2010;52:275–82.

31. Stern D, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation end products: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev 2002;54:1615–25.

32. Thouvery C, Caverzasio J. Focus on the p38 MAPK signaling pathway in bone development and maintenance. BoneKey Rep 2015;4:711–8.

33. Tang M, Peng Z, Mai Z, et al. Fluid shear stress stimulates osteogenic differentiation of human periodontal ligament cells via the extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase signaling pathways. J Periodontol 2014;85:1806–13.

34. Yan W, Chao D, Kun Y, Xiaoxia C, Qi L, Yan J. Canonical Wnt signaling pathway of the osteogenic differentiation of human periodontal ligament stem cells induced by advanced glycation end products. Hua xi kou qiang yi xue za zhi 2015;33:627–32.

35. Nusse R. Wnt signaling. CSHPerspect Biol 2012;4:11163.

36. Liu N, Shi S, Deng M, et al. High levels of β-catenin signaling reduce osteogenic differentiation of stem cells in inflammatory microenvironments through inhibition of the noncanonical Wnt pathway. J Bone Miner Res 2011;26:2082–95.

37. Liu W, Konermann A, Guo T, Jäger A, Zhang L, Jin Y. Canonical Wnt signaling differently modulates osteogenic differentiation of mesenchymal stem cells derived from bone marrow and from periodontal ligament under inflammatory conditions. BBA-Gen Subjects 2014;1840:1125–34.

38. Lalla E, Lamster IB, Feit M, et al. Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest 2000;105:1117–24.

39. Muhammad AN. Prevalence of periodontal disease, its association with systemic diseases and prevention. Int J Health Sci 2017;11:72–80.